MRSN stock forecast
Our latest prediction for Mersana Therapeutics, Inc.'s stock price was made on the July 3, 2017 when the stock price was at 13.82$.
In the short term (2weeks), MRSN's stock price should outperform the market by 3.66%. During that period the price should oscillate between -2.11% and +3.56%.
In the medium term (3months), MRSN's stock price should outperform the market by 7.51%. During that period the price should oscillate between -4.00% and +8.43%.Get email alerts
About Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
At the moment the company generates 13M USD in revenues.
On its last earning announcement, the company reported a loss of -2.10$ per share.
The book value per share is 1.97$
Three months stock forecastJuly 3, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|